BC
CRSP icon

Bartlett & Co’s CRISPR Therapeutics CRSP Stock Holding History

Bartlett & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$714K Hold
11,100
– – 0.01% 312
2023
Q3 		$504K Hold
11,100
– – 0.01% 336
2023
Q2 		$623K Hold
11,100
– – 0.01% 312
2023
Q1 		$502K Hold
11,100
– – 0.01% 290
2022
Q4 		$451K Hold
11,100
– – 0.01% 304
2022
Q3 		$725K Buy
11,100
+6,000
+118% +$435K 0.02% 239
2022
Q2 		$310K Sell
5,100
-8,500
-63% -$500K 0.01% 320
2022
Q1 		$854K Hold
13,600
– – 0.01% 239
2021
Q4 		$1.03M Buy
+13,600
New +$1.19M 0.02% 230

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bartlett & Co's CRSP Position: Q4 2023 in Review

Bartlett & Co held its CRISPR Therapeutics (CRSP) position steady in Q4 2023 at 11,100 shares worth $714K. The position accounts for 0.01% of the portfolio, ranked #312.

Bartlett & Co first reported a position in CRSP in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.03M in Q4 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Bartlett & Co held 11,100 shares of CRISPR Therapeutics worth $714K as of Q4 2023.
  • Bartlett & Co left its CRISPR Therapeutics share count unchanged in Q4 2023.
  • CRISPR Therapeutics made up 0.01% of Bartlett & Co's portfolio in Q4 2023, its #312 holding.
  • Bartlett & Co first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • Bartlett & Co's CRISPR Therapeutics position peaked at $1.03M in Q4 2021.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.